Sullivan Mark 4

What Happened
Mark Sullivan, Chief Legal Officer of Definium Therapeutics (DFTX), sold 10,702 common shares on March 25, 2026 in open-market/private transactions (reported as “S”). The weighted-average sale price was $18.47, for total proceeds of approximately $197,666. The filing indicates the sales were sell-to-cover transactions to satisfy withholding tax on vested restricted stock units.

Key Details

• Transaction date: March 25, 2026; Form 4 filed March 26, 2026 (timely).
• Shares sold: 10,702; weighted-average price: $18.47; total proceeds: ~$197,666.
• Price range: $18.36 to $18.80 across multiple trades (filing provides weighted avg and range; per-trade breakdown available on request) (F2).
• Reason: Sell-to-cover to satisfy withholding tax on vested RSUs, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted March 14, 2024 (F1).
• Ownership after transaction: Not specified in the filing.
• Additional note: Filing states an amount includes 793 shares acquired under the 2024 Employee Share Purchase Plan (ESPP) (F3).

Context
These sales were routine sell-to-cover transactions tied to RSU vesting and a pre-established 10b5-1 plan, which are commonly used to satisfy tax obligations and do not necessarily signal a change in the insider’s view of the company. Purchases generally carry more weight as signals; this sale appears administrative in nature.